 | Up a level |
Journal Article
Einsele, H., Vogel, M., Mueller, J., Knop, S., Kropff, M., Langer, C., Sayer, H., Jung, W., Wandt, H., Bassermann, F., Gramatzki, M., Roesler, W., Brugger, W., Engelhardt, M., Fischer, T., Giagounidis, A., Heidemann, E., Kroeger, N., Sezer, O., Bentz, M., Pfreundschuh, M., Salwender, H., Ludwig, W. -D., Roellig, C., Staib, P., Runde, V., Scheid, C., Ostermann, H., Hess, G., Hebart, H., Repp, R., Hart, C., Frickhofen, N., Straka, C. and Pflueger, K. -H. (2015). RESULTS FROM TWO PHASE 3 STUDIES OF POST-TRANSPLANT BORTEZOMIB (BTZ) CONSOLIDATION VS OBSERVATION (OBS) IN PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA (NDMM). Haematologica, 100. S. 151 - 152. PAVIA: FERRATA STORTI FOUNDATION. ISSN 0390-6078
Kroeger, N., Brand, R., Niederwieser, D., Platzbecker, U., Huebel, K., Weber, T., Robin, M., Stelljes, M., Afanasiev, B., Heim, D., Deliliers, G. Lambertenghi, Onida, F., Dreger, P., Pini, M., Guidi, S., Volin, L., Gramatzki, M., Bethge, W., Poire, X., Kobbe, G., van Os, M., Iacobelli, S. and de Witte, T. (2015). RIC vs. MAC followed by allogeneic stem cell transplantation for patients with MDS or secondary AML: A prospective, randomized phase III study of the CMWP of the EBMT (RICMAC-Trial). Bone Marrow Transplant., 50. S. S5 - 1. LONDON: NATURE PUBLISHING GROUP. ISSN 1476-5365
Kroeger, N., Brand, R., Niederwieser, D., Platzbecker, U., Huebel, K., Weber, T., Robin, M., Stelljes, M., Afanasiev, B., Heim, D., Deliliers, G. Lambertenghi, Onida, F., Dreger, P., Pini, M., Guidi, S., Volin, L., Gramatzki, M., Bethge, W., Poire, X., Kobbe, G., van Os, M., Iacobelli, S. and de Witte, T. (2015). RIC vs. MAC followed by allogeneic stem cell transplantation for patients with MDS or secondary AML: A prospective, randomized phase III study of the CMWP of the EBMT (RICMAC-Trial). Bone Marrow Transplant., 50. S. S5 - 1. LONDON: NATURE PUBLISHING GROUP. ISSN 1476-5365
Scheid, C., Roellig, C., Weisel, K., Salwender, H-J, Gramatzki, M., Edmaier-Schroeger, K., Sy, O. and Goldschmidt, H. (2018). Durable progression-free survival benefit in early responders to elotuzumab plus lenalidomide and dexamethasone (ELd): analysis of ELOQUENT-2 4-year data in relapsed/refractory (RR) multiple myeloma (MM). Oncol. Res. Treat., 41. S. 189 - 190. BASEL: KARGER. ISSN 2296-5262